The binding of CD44 to osteopontin, which is also abundant in brain tumors, leads to enhanced CD44 cleavage and the released CD44-ICD enhances the expression of hypoxia-inducible factor HIF-2α, promoting a hypoxic response in necrotic and perivascular areas [21]. The gene discussed is CD44; the disease is brain neoplasm.